Peptide Database

A fusion protein combining the ligand-binding domain of the activin type IIB receptor (ACVR2B) with the Fc region of human IgG1. Acts as a decoy receptor for multiple TGF-beta superfamily members including myostatin, activin A, GDF-11, and BMP9, simultaneously blocking all of them to produce dramatic increases in muscle mass.

A synthetic analog of growth hormone-releasing hormone (GHRH) that extends the half-life of endogenous GHRH. One of the most popular peptides for muscle growth and fat loss when stacked with a GHRP like Ipamorelin.

A synthetic 29-amino acid GHRH analog with 4 amino acid substitutions that improve stability and receptor affinity compared to Sermorelin. Unlike CJC-1295 DAC, it has no Drug Affinity Complex, giving it a short 30-minute half-life that mimics the body's natural pulsatile GHRH secretion when co-administered with a GHRP.

A truncated 315-amino acid isoform of follistatin that lacks the heparin-binding domain, giving it a shorter half-life and more localized action compared to Follistatin-344. Still potently inhibits myostatin and activin for muscle growth but with a different distribution profile.

A naturally occurring protein that inhibits myostatin and activin, effectively removing the biological ceiling on muscle growth.

A second-generation GHRP with high GH-releasing potency and a cleaner side effect profile than GHRP-6. Less appetite stimulation makes it preferable for body recomposition.

One of the first synthetic GHRPs developed, GHRP-6 is a potent GH secretagogue that also significantly stimulates appetite through ghrelin receptor activation.

A synthetic hexapeptide GHRP with the highest GH-releasing potency among the GHRP family. Notable for both its muscle-building effects and documented cardiovascular benefits.

A truncated analog of IGF-1 missing the first 3 amino acids from the N-terminus. This modification dramatically reduces its affinity for IGF-binding proteins (IGFBPs), making it approximately 10x more potent than native IGF-1 at the receptor level, with a much shorter half-life ideal for local/acute muscle actions.

A long-acting analog of IGF-1 with a modified arginine substitution that extends its half-life. Directly stimulates muscle protein synthesis independent of GH.

A selective growth hormone secretagogue and ghrelin mimetic that stimulates GH release without significantly elevating cortisol or prolactin. One of the cleanest and most widely used peptides for body recomposition.

A splice variant of IGF-1 released in muscle fibers in response to mechanical damage. Activates muscle satellite cells to initiate repair and hypertrophy.

A non-peptide, orally active growth hormone secretagogue that mimics ghrelin, significantly elevating GH and IGF-1 levels. Unique in being orally bioavailable.

The PEGylated (polyethylene glycol-conjugated) form of Mechano Growth Factor (MGF), extending its extremely short native half-life from minutes to 24-72 hours. This systemic form activates muscle satellite cells throughout the body rather than only at the injection site, making it suitable for systemic muscle recovery and anti-aging applications.

A 29-amino acid synthetic analog of endogenous GHRH that stimulates natural GH production. Clinically used for GH deficiency and widely used in anti-aging medicine as a safer alternative to exogenous HGH.

An FDA-approved synthetic GHRH analog originally developed to treat HIV-associated lipodystrophy. Highly effective at reducing visceral adipose tissue.